Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.

Genomes are key to unlocking life's evolutionary history. The presence and absence of certain genetic sequences and mutations ...

TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. Preserves DNA integrity in challenging clinically ...

Record free cash flow of approximately $700 million and achieved net cash position Increased 2025 share buyback target by 20% ...

NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2025 following ...

“These results are encouraging, highlighting TET2-mutated clonal hematopoiesis as a potential biomarker to select patients ...

Twist Bioscience is advancing synthetic DNA manufacturing with innovation but remains at the lower end of its 52-week range.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q3 CY2025 results , with sales up 11.9% year on year ...

NeoGenomics Inc. ( ($NEO) ) has released its Q3 earnings. Here is a breakdown of the information NeoGenomics Inc. presented to its investors.

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...